The FDA has long used accelerated approval to speed the availability of drugs for cancer and other deadly conditions.
The FDA is requiring Biogen to continue studying the drug in a trial of people who carry the genetic mutation but do not yet have ALS symptoms.
The drug, tofersen, is designed to block the genetic messengers that produce a toxic form of protein that is thought to drive the disease in about 2% of ALS patients. Cambridge, Massachusetts-based Biogen will sell it under the brand name Qalsody. Patients receive three initial spinal injections of the drug over a two-week period, followed by a monthly dose. The most common side effects linked to the drug were pain, fatigue and increased spinal fluid.
But those who received tofersen showed significant changes in levels of the toxic protein and a second neurological chemical that is considered a key indicator of the disease's progression.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Drug for rare form of Lou Gehrig’s disease OK'd by FDAU.S. health regulators have approved a first-of-a-kind drug for a rare form of Lou Gehrig’s disease
Baca lebih lajut »
FDA Approves Drug for Rare Form of Lou Gehrig's DiseaseApproval came via FDA’s accelerated pathway, which allows drugs to launch based on promising early results, before they’re confirmed to benefit patients.
Baca lebih lajut »
Drug for rare form of Lou Gehrig’s disease OK'd by FDAU.S. health regulators have approved a first-of-a-kind drug for a rare form of Lou Gehrig’s disease. The Food and Drug Administration approved Biogen's infused drug for patients with a rare genetic mutation that affects less than 500 people in the U.S. The drug is the first intended to treat an inherited form of ALS, or amyotrophic lateral sclerosis, which destroys nerve cells needed for basic functions. Tuesday's approval came despite a company study that failed to meet its goal of significantly slowing the disease. The drug did make a difference on laboratory measures of ALS. The FDA is requiring additional research to confirm the drug's benefit.
Baca lebih lajut »
Foghorn Therapeutics stock slides 21% after FDA puts partial clinical hold on cancer drug trialFoghorn Therapeutics Inc.’s stock slid 21% in premarket trade Monday, after the biotech said the Food and Drug Administration has placed a partial hold on a...
Baca lebih lajut »
FDA grants accelerated approval for Biogen ALS drug that treats rare form of the diseaseThe FDA's approval requires Biogen to further study its ALS drug tofersen to further verify its clinical benefits.
Baca lebih lajut »
Drug for rare form of ALS disease OK’d by FDABiogen’s injectable drug is for patients with a rare genetic mutation that’s estimated to affect less than 500 people in the U.S.
Baca lebih lajut »